They studied a large number of patients with urothelial carcinoma who were taking an anti-PD-L1 medication and discovered that a favorable immune response was connected to CD8+T effector cell phenotype and tumor mutation burden (TMB) (50). This evidence concerns the gene CD274 and urothelial carcinoma.